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A B S T R A C T
The aim of this study was to investigate the relationship between antiepileptic drug (AED) utilization and patient age
in a population of patients treated by primary health care physicians. Data were collected by using questionnaires com-
pleted by family physicians and paediatricians working in primary health care. Only patients with active epilepsy con-
firmed previously by neurologists or neuropaediatricans were included. One hundred and twenty-three physicians pro-
vided the requested data for 966 patients (range 1–92 years). Most frequently prescribed AEDs were barbiturates (BARB)
(37%) and carbamazepine (CBZ) (37%). Valproic acid derivates (VPA) were prescribed in 28%, but the rate was higher
(51%) in children. By calculating the correlation between age and the prescription of single AEDs across the whole sam-
ple, linear correlations were found for BARB (r=0.94; p<0.01), VPA (r=–0.93; p<0.01) and for topiramate (TPM) (r=
–0.90; p<0.01). Since our results showed significant correlations between age and the use of the majority of AEDs, we
concluded that the age may be considered a methodological bias in the presentation of data. Therefore we calculated AED
utilization as the age-adjusted prevalence rates (per/1000 inhabitants). For the most commonly prescribed AEDs they
were: BARB 1.8 (95% CI 1.6–2.0), CBZ 1.9 (95% CI 1.7–2.1), VPA 1.3 (95% CI 1.1–1.5), lamotrigine (LTG) 0.7 (CI 95%
0.6–0.8), TPM 0.6 (CI 95% 0.5–0.7). In conclusion, the age of patients has a significant impact on the prescription pat-
terns not only between children and adults, but at every age. Therefore we suggest that reporting of AED utilization pat-
tern should also include age-standardized prevalence rates of individual AED utilization.
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Introduction
Information on antiepileptic drug (AED) utilization is
an objective parameter that is useful in the evaluation of
the standard of care of people with epilepsy (PwE) in dif-
ferent social environments 1–4. In developing countries
the utilization pattern of AEDs is influenced by the abso-
lute or relative unavailability of some AEDs. In other
countries the differences may be the result of different
clinical practices, but they may also be influenced by
age-related differences in the studied populations. It is
known that the age of the patient is one of the important
factors influencing the choice of AED in an individual pa-
tient, but when the utilization structure in different popu-
lations is reported, it is usually reported for the whole
population2,3,5–8, for children only9–11 or for adults only1,12.
According to the studies published in the last twenty
years valproic acid (VPA) was the predominant AED in
therapy of children2,9–11,13, whereas in adult populations the
most frequently reported AEDs are carbamazepine (CBZ)
and phenobarbital (PB), and somewhat less frequenty
VPA, oxcarbazepine (OXC) and phenytoin (PHT)1–3,6–8,12.
From these data it may be concluded that AED utiliza-
tion is different in children and adult populations, but in
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the available literature we did not find any popula-
tion-based surveys focused on studying the influence of
age on the pattern of AED utilization.
The purpose of this study was to investigate the rela-
tionship between AED utilization and patient age in a
population of patients with active epilepsy treated by pri-
mary health care physicians.
Methods
The patient data were collected by using question-
naires, which were completed by primary health care
physicians (PHPs).The choice of the surveyed physicians
from all the main regions in Croatia was an unselective
one; the sole criteria for inclusion into the survey were
having a computerized patient database that enables
quick and reliable access to the required information,
and knowing the age-structure of the patients. Details
concerning the procedures of PHP selection and the com-
munication with them have been recently described14.
The diagnosis of epilepsy in all patients was previously
verified by neurologists or neuropediatricians. The PHPs
ascertained whether their patients fulfilled the criteria of
active epilepsy15 and included only those who had had at
least one seizure in the previous five years. Only data
about the therapy of patients with active epilepsy were
registered.
In Croatia all inhabitants are provided with basic
health insurance and the costs of AED therapy are reim-
bursed by the Croatian Institute for Health Insurance.
At the time of data collection (between May and July
2005), according to the Anatomical Therapeutic Chemi-
cal (ATC) classification the following drugs coded by
N03A were registered in Croatia: group of barbiturates
(BARB – phenobarbital, methylphenobarbital, primido-
ne), phenytoin (PHT), carbamazepine (CBZ), valproate
(VPA – sodium vaproate, valpromide), ethosuximide (ESX),
lamotrigine (LTG), topiramate (TPM), gabapentin (GBP),
vigabatrin (VGB), clonazepam (CZP). The PHPs are au-
thorized to prescribe all the mentioned drugs, but for
some use is restricted: LTG, TPM, GBP and VGB are al-
lowed only for refractory epilepsy confirmed by specialists.
Statistics: Statistical evaluation was performed using
the program STATISTICA ver. 6.1. StatSoft Inc. Correla-
tions between prescription of the used AEDs and the age
have been tested by linear regression analysis. Correla-
tions were calculated using the raw data. Pearson r cor-
relation coefficient was defined by the level of signifi-
cance of 99 % (p  0,01). Age-adjusted prevalence rates
were computed by the direct method using the European
standard population.
Results
A total of 123 PHPs provided the required data about
pharmacotherapy of 966 patients. The surveyed physi-
cians were providing health care to a population of 201
466 people. Mean age was 34.5 (SD 23.2) years, range
1–92 years, and 54.3% were male. To present the pre-
scription-rates of individual AEDs, we stratifyed our
sample into age-groups (0–14, 15–24, 25–34, 35–44,
45–54, 55–64, 65); this is shown in Table 1. It can be
seen that in the entire sample the predominant AEDs in
adults are BARBs and CBZ, whereas VPA was most fre-
quently prescribed in children. In the BARB group pre-
scription rates were: phenobarbital (11.1%), methylphe-
nobarbital (25.6%) and primidone (0.2%). The comparison
of the presented prescription rates in different age-groups
indicates that prescription rate of BARB rises with in-
creasing age, whereas prescription of VPA, TPM and
LTG decreases. To test statistically this finding, we made
the linear regression analysis.
Correlations between the prescription of the most
commonly used AEDs and the age of the patients were
calculated across the whole group (N=966); the individ-
ual patients’ data (age in years; prescription of single
AEDs) were used for that calculation. Significant linear
correlations between age and AED utilization, positive or
negative, were found for BARB (r=0.94; p<0.01), VPA
(r=–0.93; p<0.01) and TPM (r=–0.90; p<0.01), drugs
I. Bielen et al.: Age-Related Antiepileptic Drug Utilization, Coll. Antropol. 33 (2009) 2: 659–663
660
TABLE 1
PRECSRIPTION RATES OF AED USE IN DIFFERENT AGE-GROUPS
Number (%)
Years Patients BARB CBZ VPA LTG TPM BZP Other AED
0–14 258 44 (17.1) 44 (17.1) 131 (50.8) 34 (13.2) 56 (21.7) 7 (2.7) 18 (7.0)
15–24 129 15 (11.6) 57 (44.2) 48 (37.2) 30 (23.3) 22 (17.1) 11 (8.5) 9 (7.0)
25–34 139 51 (36.7) 67 (48.2) 34 (24.5) 25 (18.0) 20 (14.4) 18 (12.9) 11 (7.9)
35–44 103 41 (39.8) 57 (55.3) 20 (19.4) 12 (11.7) 5 (4.9) 13 (12.6) 3 (2.9)
45–54 99 52 (52.5) 40 (40.4) 13 (13.1) 12 (12.1) 12 (12.1) 5 (5.1) 2 (2.0)
55–64 103 65 (63.1) 45 (43.7) 12 (11.7) 17 (16.5) 6 (5.8) 5 (4.9) 7 (6.8)
65 135 88 (65.2) 45 (33.3) 9 (6.7) 6 (4.4) 2 (1.5) 5 (3.7) 6 (4.4)
Total 966 356 (36.9) 355 (36.7) 267 (27.6) 136 (14.1) 123 (12.7) 64 (6.6) 56 (5.8)
BARB – barbiturates: phenobarbital, methylphenobarbital, primidone, VPA – sodium vaproate, valpromide, BZP – benzodiazepines:
clonazepam, diazepam, clobazepam, CBZ – carbamazepine, LTG – lamotrigine, TPM – topiramate
that are used in our sample by 77.2% of patients with ac-
tive epilepsy. No statistically significant correlations were
found for CBZ or LTG.
Since our results showed significant correlation be-
tween age and utilization of many AEDs, we also showed
AED utilization as the age-adjusted prevalence rates of
AED users with active epilepsy. The prevalence rates
were calculated using the direct method of standardiza-
tion in relation to the European standard population.
The results are shown in Table 2. It can be seen that in
our sample BARB were most frequently precribed, but as
our results were presented as age-adjusted prevalences
CBZ was slightly more prevalent.
Prescription rates of monotherapy and polytherapy
(two or more AEDs) are shown in Figure 1. Monotherapy
was prescribed in slightly more than 2/3 of all patients.
Monotherapy was more frequent in patients 65 years of
age and in children, whereas in the other age-groups the
differences were smaller.
Disscusion and Conclusion
The results show that BARB, CBZ and VPA are the
most commonly prescribed AEDs in Croatia. This is in
keeping with the findings from other European coun-
tries1–3, 6–12,16. Although the trend of increasing utiliza-
tion of VPA and the newer AEDs in Croatia has been
recognized17, the newer AEDs are still prescribed consid-
erably less frequently than the older AEDs, at least
partly because prescription of new AEDs is restricted to
pharmacoresistant epilepsy. PHT, the cheapest AED ava-
ilable in Croatia, is, however, rarely prescribed. We be-
lieve that this is attributable to marketing neglect and to
the perception of PHT as a drug with a narrow therapeu-
tic range related to possible adverse side-effects.
The data about use of polytherapy in nearly 1/3 of pa-
tients corresponds roughly to the published literature.
Although in comparable population-based studies the
use of combination therapy was as high as 45%5, in the
more recent literature polytherapy was prescribed in the
range of 17–26%1–3,7–8. In our survey polytherapy was
less frequent in children and in older persons, which
could be related to the higher prevalence of newly diag-
nosed epilepsy in those ages and consecutive initial mo-
notherapy.
Based on the literature review and the results of our
investigation, it seems that the age-related differences in
AED utilization between children and adults are most
evident. In our study, and in the vast majority of the pub-
lished surveys, VPA is the main AED used in children
with epilepsy2,9–11,13. This might be a reflection of child-
hood epilepsy which is characterized by generalized sei-
zure types requiring broad-spectrum AEDs such as VPA.
In our study the prescription rate of VPA showed a con-
stant gradual decrease correlating with increasing age.
The BARB were considerably less frequently used in chil-
dren than in adults. However, as recently reported18, in
Croatia they are still rather frequently prescribed in pre-
school children (25% in the age-group 0–7 years). In part,
high proportion of BARB in this age-groupmay be related
to the attitude that BARB can be considered as first-line
treatment for seizures in neonatal period19–20.
We found a high utilization rate of BARBs and a high
correlation between the BARB prescription rate and in-
creasing age. We are aware that high prescription rates
of BARBs in the older age group found here is not in har-
mony with contemporary attitudes. For epilepsy in the
elderly, which is characterized by high incidence and
prevalence21–23, LTG and GBP are commonly recomme-
nded24–25, but even in the most developed countries these
recommendations have not been fully implemented in
clinical practice26. However, the information about subo-
ptimal therapy and previously reported inadequate dia-
gnosis14 might indicate that older PwE in Croatia are
still a neglected population. It is possible that a consider-
able proportion of aged people with epilepsy are not un-
der regular specialist review. These patients are treated
by the primary health physicians who may be not ade-
quatelly informed about the current recommendations
for epilepsy treatment.
Our results have confirmed differences in the pre-
scription pattern of antiepileptic therapy between chil-
dren and adults, but they have also shown a significant
correlation between the age and the use of some com-
monly used AEDs within the adult population.
When our sample is taken as an integral group, with-
out subdivision into age-groups, it has been found that

















Fig. 1. Prescription rates of monotherapy and polytherapy.
TABLE 2
AGE –ADJUSTED PREVALENCE RATES OF AED USERS WITH







BARB 356 (36.9) 1.8 1.6–2.0
CBZ 355 (36.7) 1.9 1.7–2.1
VPA 267 (27.6) 1.3 1.1–1.5
LTG 136 (14.1) 0.7 0.6–0.8
TPM 123 (12.7) 0.6 0.5–0.7
BARB – barbiturates: phenobarbital, methylphenobarbital, pri-
midone, VPA – sodium vaproate, valpromide, BZP – benzodiaze-
pines: clonazepam, diazepam, clobazepam, CBZ – carbamazepi-
ne, LTG – lamotrigine, TPM – topiramate
many of AEDs are in positive or negative correlation
with the age of patients. Although in other communities
a different type of correlation for individual AEDs could
be expected, this does not change the conclusion that the
patients’ age has a great impact on the prescription
patttern of AEDs over all ages.
Our data indicating prevalence rates of AED use
(number of AED users with active epilepsy/1000 inhabit-
ants) are very similar to the corresponding data in Italy
(prevalence of people using AEDs prescribed for epilepsy
– 6/1000; standard AEDs – 4.6/1000; new AEDs 1.4/1000)16.
However, since our results showed correlation between
age and the use of AEDs, we concluded that the age may
be considered a methodological bias in the presentation
of data. Age standardization is the dominant method cur-
rently in use to remove the effects of variation in age
structure and to facilitate comparisons of sets of age-spe-
cific epidemiological and demographic rates across popu-
lations with different age composition27. Therefore we
found it appropriate to adjust the prevalence rates to the
standard European population. Such a procedure dimin-
ishes methodological bias related to the differences in the
age structure of the studied populations and facilitates
comparisons between the data derived from different
countries or communities. The AED prevalences in our
sample and in the European standard population showed
only slight differences, but if the studied population had
an imbalanced age structure the obtained differences
could be expected to be significantly greater.Therefore
we suggest that reporting of AED utilization pattern
should also include age-standardized prevalence rates of
individual AED utilization.
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POTRO[NJA ANTIEPILEPTI^KIH LIJEKOVA KOD AKTIVNE EPILEPSIJE U OVISNOSTI O DOBI:
POPULACIJSKO ISTRA@IVANJE
S A @ E T A K
Namjera ovog istra`ivanja bila je da se unutar populacije osoba s aktivnom epilepsijom istra`i struktura potro{nje
antiepilepti~kih lijekova (AEL) u odnosu na dob pacijenata lije~enih u primarnoj zdravstvenoj za{titi. Podaci su pri-
kupljeni pomo}u upitnika koje su ispunili lije~nici obiteljske medicine i pedijatri u primarnoj zdravstvenoj za{titi iz svih
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glavnih regija Hrvatske. U istra`ivanje su uklju~eni samo pacijenti s dijagnozom aktivne epilepsije potvr|ene sa strane
neurologa ili neuropedijatra. Stotinu dvadeset i tri lije~nika je dalo podatke o 966 pacijenata (raspon dobi 1–92 godine).
Naj~e{}e propisivani lijekovi bili su barbiturati (BARB) (37%) i karbamazepin (CBZ) (37%). Derivati valproi~ne kiseline
(VPA) su bili propisivani u 28%, no s vi{om stopom u djece (51%). Ra~unaju}i korelaciju izme|u dobi i stopa propi-
sivanja svakog pojedina~nog AEL unutar cijelog uzorka, na|ene su linearne korelacije za BARB (r=0,94; p<0,01), VPA
(r=–0,93; p<0,01) i topiramat (TPM) (r= –0,90; p<0,01). Budu}i da su na{i rezultati pokazali zna~ajne korelacije iz-
me|u dobi i potro{nje ve}ine AEL, zaklju~ili smo da utjecaj dobi mo`e dovesti do metodolo{ke pogre{ke. Zbog toga smo
izra~unali potro{nju AEL kao dobno standardizirane stope prevalencije propisivanja (na/1000 stanovnika). Za naj~e{}e
propisivane AEL one su iznosile: BARB 1,8 (95% CI 1,6–2,0), CBZ 1,9 (95% CI 1,7–2,1), VPA 1,3 (95% CI 1,1–1,5),
lamotrigin (LTG 0,7) (CI 95% 0,6–0,8), TPM 0,6 (CI 95% 0,5–0,7). Zaklju~no, dob pacijenta ima zna~ajan utjecaj na
izbor propisivanog AEL u svakoj dobi, a ne samo izme|u djece i odraslih. Zbog toga predla`emo da se u prikazivanju
strukture potro{nje AEL uklju~i i dobno standardizirana stopa prevalencije propisivanja za svaki pojedina~ni AEL.
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